This Figure shows the chemical structures of the 3 different CETP inhibitors. The first one, torcetrapib, was revealed to cause more harm than good in its large clinical endpoints trial, probably due to some off-target effects such as raising aldosterone and raising blood pressure.
The 2 newer CETP inhibitors, dalcetrapib and anacetrapib, however, are currently being assessed in large clinical trials that have enrolled thousands of patients. The trial with dalcetrapib is enrolling approximately 16,000 CHD patients; the trial with anacetrapib is enrolling about 30,000 patients.
J Clin Lipidol. 2011; 5(6).